UK markets closed

Orphazyme A/S (OZYMF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.15000.0000 (0.00%)
At close: 11:36AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.1500
Open4.1500
BidN/A x N/A
AskN/A x N/A
Day's range4.1500 - 4.1500
52-week range3.8200 - 18.1000
Volume100
Avg. volume1,681
Market cap145.052M
Beta (5Y monthly)0.70
PE ratio (TTM)N/A
EPS (TTM)-3.9920
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Modified long-term share-based incentive program for 2021

    Orphazyme A/SCompany announcement No. 23/2021Company Registration No. 32266355 Copenhagen, Denmark, October 7, 2021 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)), a late-stage biopharmaceutical company, has today introduced a modified long-term incentive program for 2021 (the “LTIP”) with the view to retaining members of the Executive Management and other employees of the Group, while also creating an incentive for a positive share price development and corporate performance for the benefit of the

  • Globe Newswire

    Orphazyme provides regulatory and financial updates

    Orphazyme A/SCompany announcement No. 22/2021Company Registration No. 32266355 Copenhagen – October 5, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces regulatory updates for its investigational drug candidate, arimoclomol, for which it is seeking marketing authorization in both Europe and the United States for the treatment of Niemann-Pick disease Type C (NPC). The company also announces that it now expects to end 2021 with a cash position of no les

  • Business Wire

    Final Deadline for Investors with Losses Exceeding $500K to Actively Participate in the Orphazyme A/S (ORPH) Class Action - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, September 06, 2021--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired (1) Orphazyme American depositary shares ("ADSs") pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted